True Liquid Biopsy for Cancer from BioFluidica
BioFluidica’s next generation diagnostic platform, provides a non-invasive procedure that can be applied to many diseases where there is a need for improved diagnostics. The platform has been validated for six different cancer types, stroke, and infectious diseases. In the cancer field alone, there is a tremendous need to improve diagnostic capabilities. Globally, there are more than 14 million reported cancer cases per year. Each case being not just a number, but associated with a story of confusion, financial challenges, despair and loss. In the year 2030 it is projected that globally 11 million people will die of cancer. In the U.S. alone, there were more than 500,000 deaths and 1.66 million new cases reported in 2014. Direct cancer care costs in the U.S. have been estimated at $125 billion in 2010 and expected to grow to $200 billion by 2020.
Better cancer detection, and subsequent personalized treatment, precision medicine, are keys to improve patient treatment and outcomes. Detection of novel biomarkers, such as Circulating Tumor Cells, CTCs, are leading the way to improved diagnostics. The global market for CTC based diagnostics alone is estimated to reach almost $9 billion by 2018, with a compounded annual growth rate of 18.9% for 2013 – 2018*) . In order to improve the survival rate for many cancer diseases, the field of oncology needs better therapies and optimized personalized patient treatment. This will require the evolution of better technologies. BioFluidica is now delivering these new and improved technologies for the analysis of circulating markers, fullfilling the promise of a true liquid biopsy.
Rolf Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development, and successful product launch into global markets. Prior to joining BioFluidica he was the Founder and President of Biomatrica, which he developed from an idea to a global leader in biopreservation technologies for diagnostic and healthcare companies. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris France.
Kim Kamdar, Ph.D., Partner, Domain Associates
Kim joined Domain in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Kim has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine.
Present board memberships include Epic Sciences, Neothetics, Obalon Therapeutics, Omniome, ROX Medical, Sera Prognostics, and Tragara Pharmaceuticals. She was formerly a board member of Syndax Pharmaceuticals. Kim was also involved with Ariosa Diagnostics until the company was sold to Roche in January 2015, Corthera until the company was sold to Novartis in February 2010 and BiPar Sciences until that company was sold to sanofi-aventis in April 2009.
Prior to Domain, Kim was a Kauffman Fellow with MPM Capital. Prior to joining MPM, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Kim is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.
Kim serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and of Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego’s CONNECT Foundation.
5:30: Registration, Networking, food and drinks
7:30: Audience Q & A
8:00: Program Concludes, Networking, Coffee & Dessert until 8:30
REGISTRATION & COST
MITEF Members and MITEF Sponsors: Free
MIT Alums: $50
NOTE: Online Registration ends at 11AM, the day of the event. If you register online after 11AM, you will be charged $75, the on-site price. No refunds after February 18.
PAYPAL is our payment processor and accepts ALL MAJOR Credit Cards.